ProMIS Neurosciences Inc (NAS:PMN)
$ 14.82 -0.0050 (-0.03%) Market Cap: 132.90 Mil Enterprise Value: 69.05 Mil PE Ratio: 0 PB Ratio: 2.19 GF Score: 35/100

ProMIS Neurosciences Inc Webinar on PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease Transcript

Jul 28, 2026 / 12:00PM GMT
Release Date Price: $14.52 (+23.89%)
Operator

Good morning and welcome to the PROMIS Neurosciences webinar on the PRECISE-AD Phase 1B trial of PMN310 in Alzheimer's disease. At this time, all attendees are in a listen-only mode and a question-and-answer session will follow the formal presentation and fireside chat. As a reminder, this call is being recorded and a replay will be made available on the PROMIS Neurosciences website following the conclusion of the event.

I'd now like to turn the call over to Neil Warma, President and Chief Executive Officer of PROMIS Neurosciences. Please go ahead, Neil.

Neil Warma
ProMIS Neurosciences Inc - President, Chief Executive Officer, Director

Thank you very much, Tara, and thank you everybody for joining today for this update. My name is Neil Warma, CEO of PROMIS Neurosciences.

And today we will give an overview of our blinded six month interim analysis from our PRECISE-AD Phase 1B clinical trial in Alzheimer's disease.

I would like to remind everybody to please review our forward-looking statements. We are a publicly listed company.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot